Sam Ahn, MD
Allergy & Immunology · Napa, CANPI 1558423814
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.3%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Bio Products Laboratory USA, Inc. at 28.1% of the total.
Across 498 payments — averaging $49.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bio Products Laboratory USA, Inc.$7K
- Genentech USA, Inc.$4K
- Sanofi$3K
- AstraZeneca$2K
- Optinose US, Inc.$1K
- GSK$1K
- plus $7K from 39 others
Across 26 payments — averaging $3079.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$53K
- Sanofi US Services Inc.$26K
- Novartis$454
What the payments were for
- Consulting fees$4,86120%
- Speaking & faculty fees$5,00020%
- Travel & lodging$1,1225%
- Food & beverage$13,69555%
- Education$1070%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,785 in reported general payments places this provider in the 85th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 73 | $306,236 |
| XolairOmalizumab | 70 | $195,687 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 24 | $176,103 |
| TezspireTezepelumab-Ekko | 37 | $142,367 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 120 | $92,258 |
| Spiriva RespimatTiotropium Bromide | 33 | $32,721 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $20,512 |
| Ipratropium Bromide | 256 | $13,751 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $13,029 |
| AlvescoCiclesonide | 17 | $11,470 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $11,270 |
| Qvar RedihalerBeclomethasone Dipropionate | 20 | $10,927 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $10,053 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 53 | $9,091 |
| DuleraMometasone/Formoterol | 23 | $8,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $97 | $195,68770 claims |
| Bio Products Laboratory USA, Inc.Gammaplex | $6,963 | $176,10324 claims |
| AstraZenecaTezspire, Symbicort | $1,796 | $152,42070 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,179 | $130,114202 claims |
| Boehringer IngelheimSpiriva Respimat | $155 | $32,72133 claims |
| Covis Pharma GmbHAlvesco | $14 | $11,47017 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $254 | $10,92720 claims |
| MerckDulera | $44 | $8,27523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Napa
- Raffi TachdjianSanta Monica$3.7M
- Bob GengSan Diego$3.3M
- Vinay MehtaLaguna Niguel$1.3M
- Andrew WhiteSan Diego$752K
- Marc RiedlSan Diego$725K
- Katharine WoessnerSan Diego$581K
- Brian Modenala Jolla$453K
- Heena Shah PatelUpland$428K
- Jacob OffenbergerGranada Hills$419K
- Myron LiebhaberSanta Barbara$354K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.